November 21, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform.
On November 21, 2024, the committee will discuss and make recommendations on supplemental biologics license application (sBLA) 125586/546 from Astra Zeneca for Andexxa (coagulation factor Xa (recombinant), inactivated -zhzo), for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
